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Background: The global burden of diabetes mellitus and other chronic diseases is high, and 80% of those with
diabetes now live in low and middle income countries. Yet, little information is available regarding prevalence of
diabetes and intermediate hyperglycemia in these countries, especially when a full range of diagnostic tests is
employed. The purpose of this study is to provide a full accounting of these prevalences in a large, free-living
Brazilian population.
Methods: We report baseline data (2008-2010) from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), a
cohort study of 15,105 civil servants aged 35-74 years. Diabetes mellitus was ascertained by self-report of diagnosis,
medication use, fasting glucose, an oral glucose tolerance test, and/or glycated hemoglobin. Cut-offs for diabetes
and intermediate hyperglycemia followed the recommendations of the World Health Organization and the American
Diabetes Association. Adjusted prevalences were estimated through logistic regression.
Findings: With this full accounting, 19.7% (19.0%-20.3%) had diabetes mellitus, 50.4% being previously undiagnosed.
Frequencies of intermediate hyperglycemia according to various criteria ranged from 16.1% to 52.6%. Diabetes or
intermediate hyperglycemia was present in 79.1% of participants when using the most comprehensive definitions. The
burden was greatest in the elderly, the obese, non-whites, and those with less formal education (p < 0.001).
Interpretation: That four of every five free-living individuals aged 35-74 years working in selected public institutions in
six Brazilian state capitals presented either diabetes or intermediate hyperglycemia highlights the advanced stage of
the obesity – diabetes epidemic in urban Brazil and indicates the need for urgent action.
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The United Nations has declared that the global burden
of chronic non-communicable diseases (NCDs) consti-
tutes one of the major challenges for development in the
21st century, particularly for developing countries. Diabetes
mellitus (diabetes) along with cancer, cardiovascular
and chronic respiratory diseases represent about 80% of
the NCD mortality [1]. Additionally, diabetes is one of* Correspondence: maria.schmidt@ufrgs.br
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unless otherwise stated.the 10 main causes of global disease burden when eval-
uated by years of life lived with disability [2].
The prevalence of diabetes has risen dramatically in
the last decades. The International Diabetes Federation
(IDF) estimated that 382 million people in 2013 had dia-
betes, 175 million (46%) being undiagnosed [3]. Based
on the IDF estimates, 80% of the cases of diabetes globally
live in low and middle income countries. In absolute
numbers, Brazil was ranked 4th among all nations. Yet,
prevalence of diabetes in Brazil has been largely based
on self-reported cases, given the difficulties in conduct-
ing large surveys with laboratory determinations.
The only Brazilian study which included blood glucose
measurement and was not based in just one locall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prevalence of 7.6% in adults 30-69 years of age of vari-
ous capitals of different geographic regions [4]. This
prevalence certainly underestimates current rates given
the epidemiologic and nutritional transitions that have
occurred in Brazil over the last decades [5]. Estimates
for impaired glucose tolerance (IGT) [3] and other cat-
egories of risk based on fasting glucose (impaired fasting
glucose, IFG) or glycated hemoglobin (elevated HbA1C)
[6], frequently referred to as intermediate hyperglycemia
or prediabetes, are also either outdated or restricted to
local settings.
Thus, to gain insight in terms of the current burden of
diabetes and intermediate hyperglycemia with a full ac-
counting of diagnostic laboratory exams (fasting glucose,
a 75 g oral glucose tolerance test and a measurement of
HbA1C), the objective of this study is to describe their
prevalence, overall and according to sociodemographic
and nutritional variables, in the baseline examination of
a large cohort of Brazilian adults conducted in six capi-
tals of Brazil, thus allowing for a broad representation of
major relevant population groups.
Methods
The Brazilian Longitudinal Study of Adult Health (ELSA-
Brasil) is a prospective cohort study designed to investi-
gate diabetes, cardiovascular and other related chronic
diseases, as previously described [7,8]. The ethics commit-
tee of all institutions approved the research protocol, and
all participants gave written consent.
Active or retired civil servants (35-74 years) of univer-
sities or research institutions from six state capitals of
three different regions of Brazil were invited to partici-
pate, totalizing, in 2008, 52,137 potential volunteers.
Men, the elderly, and those whose activities did not re-
quire a higher education were especially encouraged to
participate. A total of 16,435 expressed interest, 15,821
being pre-enrolled. Between 2008 and 2010, 15,105 sub-
jects completed the baseline examination. After exclud-
ing three participants who lacked laboratory values, our
final sample for analyses comprises 15,102 participants.
A previously validated, comprehensive set of question-
naires, clinical measurements and laboratory tests was
carried out. Sociodemographic factors and past medical
history were ascertained by questionnaire. Participants
were requested to bring their medications or prescrip-
tions to the clinic. Weight and height were measured
using standard equipment and techniques. A 12-hour
fasting blood sample was drawn in the morning soon
after arrival at the research clinic, following standardized
procedures for samples collection and processing [9]. A
standardized 75 g oral glucose tolerance test (OGTT) was
performed in all participants without known diabetes util-
izing an anhydrous glucose solution [10]. Plasma glucosewas measured by the hexokinase method (ADVIA
Chemistry; Siemens, Deerfield, Illinois). HbA1C was mea-
sured by high-pressure liquid chromatography (Bio-Rad
Laboratories, Hercules, California), using a method certi-
fied by the National Glycohemoglobin Standardization
Program.
Diabetes status was defined in a comprehensive fash-
ion, as follows. A previously diagnosed diabetes was
classified when answering, “yes” to either “Have you
been previously told by a physician that you had/have
diabetes (sugar in the blood)?” or “Have you used medi-
cation for diabetes in the past 2 weeks?” Previously un-
diagnosed diabetes was classified based on laboratory
values when reaching the threshold for fasting plasma
glucose (FPG; ≥7.0 mmol/L), 2-hour plasma glucose
during the OGTT (2 h PG ≥11.1 mmol/L), or HbA1C
(≥6.5%; ≥47.5 mmol/mol) [11-13].
More restrictive secondary definitions were also calcu-
lated: first, by excluding those classified only on the basis
of their HbA1C value, since this test has only recently
been recommended for diagnostic purposes; second, by
only considering FPG, as this is the approach most fre-
quently used in clinical practice; and finally by also re-
quiring that the participant’s report of a previous
diagnosis be coupled with either medication use or la-
boratory confirmation.
Intermediate hyperglycemic states, among those not
meeting the comprehensive diabetes definition, used the
following cut-offs: impaired glucose tolerance (IGT), a
2 h PG ≥7.8 mmol/L; impaired fasting glucose (IFG; by
the World Health Organization – WHO – criteria), a
FPG ≥6.1 mmol/L [13], or alternatively a FPG ≥5.6 mmol/L,
according to the American Diabetes Association [11]; and
elevated HbA1C, a value ≥5.7% (≥38.8 mmol) [11] or, alter-
natively ≥6.0% (≥42.1 mmol) [14].
Race was defined by the participant’s self-declared skin
color/race. Educational level was ascertained in years
and then classified in levels. Body mass index (BMI) was
defined as weight (kg)/height (m2) and classified accord-
ing to the standard definition.
We estimated crude and adjusted prevalences and
their 95% confidence intervals through logistic regres-
sion using the procedure PROC RLOGIST and the pre-
dmarg statement in SUDAAN. Smoothing the lines of
prevalence across age was performed using a spline routine
(proc gploc; interpol = sm30, SAS). All analyses were done
using Statistical Analysis System (SAS 9.3 for Windows
software; SAS Institute, Cary, NC) and SUDAAN version
11.0. A p-value of less than 0.05 was considered statistically
significant.
Results
At baseline, mean age was 52.1 years and mean BMI
27.0 kg/m2. As seen in Table 1, we enrolled large numbers
Table 1 Selected socio-demographic and nutritional
characteristics of study participants during the baseline
of the Brazilian Longitudinal Study of Adult Health
(ELSA-Brasil), 2008-2010
n % 95% CI
Gender (n = 15102)
Men 6885 45.6 44.8-46.4
Women 8217 54.4 53.6-55.2
Age (n = 15102)
35-44 3340 22.1 21.5-22.8
45-54 5937 39.3 38.5-40.1
55-64 4233 28.0 27.3-28.8
65-74 1592 10.5 10.1-11.0
Self-identified skin color/race category
(n = 14918)
White 7789 52.2 51.4-53.0
Black 2397 16.1 15.5-16.7
Brown (“pardo”) 4201 28.2 27.4-28.9
Asian 374 2.5 2.3-2.8
Indigenous 157 1.1 0.9-1.2
Educational level (n = 15102)
Incomplete elementary school 894 5.9 5.5-6.3
Incomplete secondary school 1028 6.8 6.4-7.2
Secondary school 5232 34.6 33.9-35.4
University degree 7948 52.6 51.8-53.4
Body mass index categories (BMI) (n = 15096)
Underweight (<18.5 kg/m2) 143 1.0 0.8-1.1
Normal ( 18.5-24.9 kg/m2) 5422 35.9 35.2-36.7
Overweight (25-29.9 kg/m2) 6073 40.2 39.5-41.0
Obese (≥30 kg/m2) 3458 22.9 22.2-23.6
Small differences in total frequency (n) of characteristics are due to missing values.
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ticipants declaring as being one of the main three race/
color categories of the Brazilian population. Of note,
52.6% had a university degree and 63.1% were either over-
weight or obese.
As shown in Table 2, when utilizing all of the diagnos-
tic information available (definition 1a), the prevalence
of diabetes was 19.7% (19.0%-20.3%). By restricting the
classification of self-reported diabetes (definition 2a) to
cases reporting previous diagnosis combined with either
medication use or confirmation by laboratory testing in
ELSA, prevalence decreased to 18.4% (17.8%-19.0%).
The exclusion of HbA1C from the diagnostic criteria de-
creased total prevalence by 1.9% for each of the above
definitions, to 17.8% (17.2%-18.4%) and to 16.5% (15.9%-
17.1%), respectively. When additionally excluding the 2 h
post-load plasma glucose, prevalence decreased to 15.1%
(14.5%-15.7%) and 13.6% (13.1%-14.2%), respectively. Thepercentage of previously diagnosed diabetes was generally
similar to that of previously undiagnosed diabetes, except
when the latter was defined solely by fasting plasma
glucose.
Frequencies of previously diagnosed and undiagnosed
diabetes increased importantly with age among men and
women (Table 3). The proportion of those previously
undiagnosed (right columns) decreased with increasing
age, from 58.3% to 40.6% for the age strata of 35-44 years
to 65-74 years.
As seen in Table 4, the crude prevalence of total and
previously diagnosed diabetes was higher among men
and increased markedly with age and with increasing
BMI. Whites had a lower prevalence of diabetes than
other groups. Highest rates were seen in Asian, black
and indigenous Brazilians. A smooth gradient was seen
in terms of educational attainment, with participants
with lesser education having a notably greater preva-
lence. Adjustment for the above-mentioned variables re-
sulted in the following comparisons: Among the obese
the adjusted prevalence was 2.7 times that among the
lean; those over 65 had 4.4 times the adjusted prevalence
of those under 45; men had a 42.6% greater prevalence
than women; blacks a 37.9% and Asians (primarily of
Japanese origin) a 61.0% greater adjusted prevalence
than whites; and those not completing elementary
school a 64.6% greater adjusted prevalence than those
with a university education. Prevalence among “browns”,
a group with ethnically mixed – Caucasian, African and
to a lesser extent indigenous – ancestry, was intermedi-
ate between that seen among whites and blacks. Al-
though a generally similar pattern was seen when
considering only those previously diagnosed diabetes,
differences were accentuated across age and BMI cat-
egories; Asian, rather than indigenous Brazilians had the
highest adjusted frequency among race/color groups.
As shown in Table 5, prevalence of intermediate
hyperglycemia varied considerably according to the def-
inition used. The prevalence of IGT (20.3%) was similar
to that of IFG based on the WHO criteria (19.1%). How-
ever, the prevalence of IFG based on the ADA criteria
was much larger (52.6%). Regardless of the criteria used,
these intermediate states of hyperglycemia were higher
in men. When classified by HbA1C values, intermediate
hyperglycemia was present in 16.1% (ADA definition)
and in 7% (using the previous Expert Committee recom-
mendation), and was more common among women.
Considering that tests are frequently done together in
the clinical setting, we also analyzed test results jointly.
The frequency of intermediate hyperglycemia reached
very high values, varying from 29.9% to 59.4% depending
on the definition used (Table 5).
Table 6 shows that in both men and women, the fre-
quency of IGT increased by age categories. A similar
Table 2 Prevalence of diabetes, baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n = 15102,
2008-2010






n % 95% CI n % 95% CI n % 95% CI % 95% CI
1. Previously diagnosed (self-report or medication use)
or undiagnosed reaching:
a. diabetes cut-off for HbA1C, FPG or 2hPG 2970 19.7 19.0 – 20.3 1473 9.8 9.3 – 10.2 1497 9.9 9.4 – 10.4 50.4 48.6-52.2
b. diabetes cut-off for FPG or 2hPG 2688 17.8 17.2 – 18.4 1473 9.8 9.3 – 10.2 1215 8.0 7.6 – 8.5 45.2 43.3-47.1
c. diabetes cut-off for FPG 2280 15.1 14.5 – 15.7 1473 9.8 9.3 – 10.2 807 5.3 5.0 – 5.7 35.4 33.4-37.4
2. Previously diagnosed (restricted definition**)
or undiagnosed reaching:
a. diabetes cut-off for HbA1C, FPG or 2hPG 2778 18.4 17.8 – 19.0 1202 8.0 7.5 – 8.4 1576 10.4 10.0 – 10.9 56.7 54.9-58.6
b. diabetes cut-off for FPG or 2hPG 2486 16.5 15.9 – 17.1 1202 8.0 7.5 – 8.4 1284 8.5 8.1 – 9.0 51.7 49.7-53.6
c. diabetes cut-off for FPG 2055 13.6 13.1 – 14.2 1202 8.0 7.5 – 8.4 853 5.7 5.3 – 6.0 41.5 39.4-43.6
HbA1C = glycated hemoglobin; FPG = fasting plasma glucose; 2hPG = plasma glucose 2 h after a glucose load.
*Cases previously undiagnosed / Total cases.
**Requiring that a previous diagnosis of diabetes be accompanied by medication use or be verified by a laboratory result.
Diabetes cut offs: FPG (≥7.0 mmol/L); 2-hour PG (≥11.1 mmol/L); or HbA1C (≥6.5%; ≥47.5 mmol/mol).
Schmidt et al. Diabetology & Metabolic Syndrome 2014, 6:123 Page 4 of 9
http://www.dmsjournal.com/content/6/1/123pattern was observed with IFG defined by the WHO cri-
teria, with the exception of the oldest men. IFG (ADA)
decreased by age among men, and did not change much
among women over 45 years. Elevated HbA1C increased
slightly with age among women, but showed no clear
age trend among men. Ethnic differences in the preva-
lence of intermediate hyperglycemia categorized accord-
ing to the various definitions were generally small, the
exception being for the category defined by HbA1C, for
which blacks had a considerably greater prevalence.
Considering diabetes and intermediate hyperglycemia
together, more than half of participants presented an ab-
normality, regardless of the criteria used to define IFG. In
fact, when IFG (ADA) was considered, this combined fre-
quency reached 79.1%, leaving only 20.9% of participants
classified as having normoglycemia. Figure 1 illustrates the
fully accounted burden of diabetes and intermediate
hyperglycemia graphically, showing the cumulative per-
centage of participants presenting these conditions by age.
Of note, over 80% of participants aged 50 or greater wereTable 3 Distribution of diabetes cases* according to categorie
Study of Adult Health (ELSA-Brasil), n = 15102, 2008-2010
Previously diagnosed
Men Women Total Men
Age Strata n % n % % n
35-44 60 3.8 39 2.2 3.0 90
45-54 236 8.8 202 6.2 7.4 316
55-64 315 17.0 289 12.2 14.3 291
65-74 169 21.5 163 20.3 20.9 126
Total 780 11.3 693 8.4 9.8 823
*considering a self-reported diagnosis, use of medication, or a full accounting of gluaffected, and this fraction exceeded 90% in those above
age 65.
Discussion
The prevalence of diabetes in Brazil assessed by self-reported
has increased over the last two decades, in part due to
greater access to diagnostic testing [5]. In the late 1980s, the
prevalence was 4.1% in individuals 30-69 years residing in
various metropolitan areas [4]. In 2006, a telephone survey
based on wider age range (18 years or older), found a preva-
lence of 5.3% among adults residing in Brazilian capital cities
[15]. Conducted annually ever since with similar probabilistic
samples, this telephone survey found a prevalence of 6.8% by
2012 [16], a 28% jump in just seven years. Of note, when
using comparable diabetes definitions (self-reported diagno-
sis, without consideration of medication use) and age ranges,
the prevalence of known diabetes (8.8%) in our cohort,
which is based in six of the 22 cities covered by the annual
telephone survey, was quite comparable to that observed
(9.8%) in the 2010 telephone survey [8].s of sex and age, baseline of the Brazilian Longitudinal
Previously undiagnosed Percent undiagnosed
Women Total Men Women Total
% n % % % % %
5.8 51 2.9 4.2 60.4 56.9 58.3
11.8 251 7.7 9.6 57.3 55.4 56.5
15.7 270 11.4 13.3 48.0 48.3 48.2
16.0 102 12.7 14.3 42.7 38.5 40.6
12.0 674 8.2 9.9 51.5 49.4 50.4
cose abnormalities (Definition 1a in Table 1).
Table 4 Prevalence of total and previously diagnosed diabetes* according to selected socio-demographic and
nutritional characteristics, baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n = 14912, 2008-2010
Total diabetes Previously diagnosed diabetes
Unadjusted Adjusted** Unadjusted Adjusted**
Population correlate n % 95% CI % 95% CI P value n % 95% CI % 95% CI P value
Sex <0.0001 <0.0001
Men 1572 23.2 22.2-24.2 23.4 22.5-24.4 762 11.2 10.5-12.0 11.4 10.7-12.2
Women 1350 16.6 15.8-17.4 16.4 15.6-17.2 683 8.4 7.8-9.0 8.3 7.7-8.9
Age (years) <0.0001 <0.0001
35-44 240 7.2 6.4-8.1 7.9 7.0-8.9 99 3.0 2.4-3.6 3.2 2.7-3.9
45-54 993 16.9 16.0-17.9 16.5 15.6-17.4 432 7.4 6.7-8.0 7.1 6.5-7.8
55-64 1142 27.4 26.1-28.8 27.0 25.7-28.3 592 14.2 13.2-15.3 14.1 13.0-15.1
65-74 547 35.0 32.7-37.4 34.6 32.3-37.0 322 20.6 18.6-22.6 20.8 18.8-22.9
Body mass index (BMI) <0.0001 <0.0001
<25 kg/m2 592 10.8 9.9-11.6 11.7 10.9-12.6 268 4.9 4.3-5.4 5.3 4.8-6.0
25-29.9 kg/m2 1187 19.8 18.8-20.8 18.9 18.0-19.9 603 10.1 9.3-10.8 9.6 8.9-10.3
≥30 kg/m2 1143 33.5 31.9-35.1 32.1 30.6-33.6 574 16.8 15.6-18.1 16.0 14.8-17.2
Race/Color <0.0001 <0.0001
White 1291 16.6 15.8-17.4 17.7 16.8-18.6 634 8.1 7.5-8.8 8.6 7.9-9.3
Brown 836 19.9 18.7-21.1 19.3 18.1-20.5 406 9.7 8.8-10.6 9.6 8.7-10.5
Black 655 27.4 25.6-29.1 24.4 22.7-26.1 329 13.7 12.4-15.1 12.3 11.0-13.6
Indigenous 45 28.7 21.5-35.8 20.9 15.9-27.0 22 14.0 8.5-19.5 9.8 6.5-14.6
Asian 95 25.4 21.0-29.8 28.5 24.3-33.1 54 14.4 10.9-18.0 15.7 12.4-19.7
Educational attainment <0.0001 <0.0001
Incomplete elementary 331 37.7 34.5-40.9 26.5 24.0-29.2 177 20.1 17.5-22.8 13.2 11.4-15.3
Incomplete secondary 307 30.1 27.3-32.9 23.4 21.2-25.8 154 15.1 12.9-17.3 11.4 9.8-13.2
Secondary school 1123 21.7 20.5-22.8 22.1 21.0-23.3 555 10.7 9.9-11.6 11.2 10.3-12.1
University degree 1161 14.8 14.0-15.6 16.1 15.3-17.0 559 7.1 6.6-7.7 7.7 7.1-8.4
*considering self-reported diagnosis, use of medication, and a full accounting of glucose abnormalities (Definition 1a in Table 1).
**Adjusted for other variables in table and study center.
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tremely common suggests that the prevalence of dia-
betes will increase for several years to come. For every
one adult with diabetes in our sample, approximately
one had IGT (20.3%) and 1.5 IGT or IFG (≥6.1 mol/L;
31.0%). If the lower ADA IFG cut point (≥5.6 mol/L)
were used, almost 3 adults (56.1%) would be classified as
having either IGT or IFG for every one with diabetes.
Data from a recent meta-analysis suggest that over a
10 year period, approximately 1 in 3 of those with inter-
mediate hyperglycemia by IFG (ADA) or HbA1C criteria,
almost half of those with intermediate hyperglycemia by
IFG (WHO) or with IGT, and 70% of those with IFG
and IGT will convert to frank diabetes [6]. The relevance
of expanding the WHO definition of IFG to that of the
ADA by including fasting glucose in the 100-109 mg/dL
range is unclear, and is a major issue, as it labels a very
large fraction of the population as being at risk.Additionally, the disparities in the prevalence of inter-
mediate hyperglycemia when assessed by these different
measures and also when assessed by a specific measure
in varying age and sex groups suggest that these mea-
sures result, to a certain extent, from different processes.
Of note in this regard, elevated HbA1c was more com-
mon among blacks, which is consistent with previous
studies [17].
The time trend indicated by these Brazilian studies is
consistent with findings from around the world which
show dramatic increases in diabetes prevalence over the
past few decades [3,18]. When a similar age group is
used for comparison, our rates of diabetes are higher
than those recently reported for China and for Panama
[19,20]. The high prevalences we found for intermediate
hyperglycemia are also consistent with those previously
reported globally [3,18,19,21]. The much higher preva-
lence we found for IFG based on the ADA criteria in
Table 5 Prevalence of intermediate states of hyperglycemia,* baseline of the Brazilian Longitudinal Study of Adult
Health (ELSA-Brasil), n = 15102, 2008-2010
Total Men (n = 6885) Women (n = 8217)
n % 95% CI n % 95% CI n % 95% CI
IGT 3064 20.3 19.7-20.9 1455 21.1 20.2-22.1 1609 19.6 18.7-20.4
IFG (WHO) 2886 19.1 18.5-19.7 1680 24.4 23.4-25.4 1206 14.7 13.9-15.4
IFG (ADA) 7946 52.6 51.8-53.4 4050 58.8 57.7-60.0 3896 47.4 46.3-48.5
Intermediate HbA1C (ADA)** 2431 16.1 15.5-16.7 1011 14.7 13.9-15.5 1420 17.3 16.5-18.1
Intermediate HbA1C ≥6.0%*** 1049 7.0 6.5-7.4 433 6.3 5.7-6.9 616 7.5 6.9-8.1
IFG (WHO) or IGT 4684 31.0 30.3-31.8 2406 35.0 33.8-36.1 2278 27.7 26.8-28.7
IFG (ADA) or IGT 8472 56.1 55.3-56.9 4217 61.3 60.1-62.4 4255 51.8 50.7-52.9
IFG (WHO) or Intermediate HbA1C(ADA) 4514 29.9 29.2-30.6 2266 32.9 31.8-34.0 2248 27.4 26.4-28.3
IFG (ADA) or Intermediate HbA1C (ADA) 8532 56.5 55.7-57.3 4210 61.2 60.0-62.3 4322 52.6 51.5-53.7
IGT, IFG (WHO) or Intermediate HbA1C(ADA) 5929 39.3 38.5-40.0 2852 41.4 40.3-42.6 3077 37.5 36.4-38.5
IGT, IFG (ADA) or Intermediate HbA1C(ADA) 8971 59.4 58.6-60.2 4356 63.3 62.1-64.4 4615 56.2 55.1-57.2
*After excluding diabetes defined by a self report, medication use or elevated HbA1C, fasting plasma glucose or plasma glucose 2 h after a glucose load.
**HbA1C ≥5.7% (≥38.8 mmol).
***HbA1C ≥6.0% (≥42.1 mmol).
IGT = impaired glucose tolerance; IFG = impaired fasting glucose; ADA =American Diabetes Association; WHO=World Health Organization; HbA1C = glycated hemoglobin.
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cemic states has been previously described [22].
The burden of diabetes we observed in specific sub-
groups is remarkable. A total of 27.5% of those between
55 and 64 years of age had diabetes, this percentage
rising to 35.2% for those aged 65 to 74. Of note, this
latter percentage of 35.2% reflects an individual’s prob-
ability of developing diabetes across the lifespan, a
probability which is not readily perceived when risk is
expressed as mean diabetes prevalence among adultsTable 6 Distribution of intermediate hyperglycemia categorie
Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n
Impaired glucose tolerance Impaired fasting glucose (W
Men Women Total Men Women T
n % n % % n % n %
Total 1455 21.1 1609 19.6 20.3 1680 24.4 1206 14.7 1
Age
35-44 263 16.9 286 16.1 16.4 286 18.3 132 7.4 1
45-54 556 20.7 606 18.6 19.6 681 25.4 471 14.4 1
55-64 428 23.1 477 20.1 21.4 512 27.6 444 18.7 2
65-74 208 26.4 240 29.9 28.1 201 25.5 159 19.8 2
Race/Color
(n = 14918)
White 804 22.3 828 19.8 21.0 895 24.9 597 14.2 1
Brown 405 20.0 440 20.2 20.1 478 23.6 338 15.5 1
Black 179 19.0 250 17.2 17.9 215 22.9 209 14.4 1
Indigenous 19 20.7 10 15.4 18.5 23 25.0 14 21.5 2
Asian 29 22.7 66 26.8 25.4 40 31.3 32 13.0 1
*After excluding diabetes defined by self-report, medication use or HbA1C, FPG or 2
**HbA1C ≥5.7% (≥38.8 mmol).≥18 years of age, especially when this is based on self-
report (e.g. 7.4%). Similarly, 33.7% of all obese partici-
pants had diabetes. More than 25% of all blacks, those
of Asian descent and indigenous Brazilians, and more
than 30% of all those with less than a high school edu-
cation had diabetes. In fact, with full accounting and
using the ADA definition of IFG, only 12.8% of obese
participants, and only 10.9% of participants greater
than 65 years of age, could be classified as having
normoglycemia.s* according to sex, race and age, baseline of the
= 15102, 2008-2010
HO) Impaired fasting glucose (ADA) Intermediate HbA1C**
otal Men Women Total Men Women Total
% n % n % % n % n % %
9.1 4050 58.8 3896 47.4 52.6 1011 14.7 1420 17.3 16.1
2.5 976 62.5 675 37.9 49.4 240 15.4 244 13.7 14.5
9.4 1635 61.0 1605 49.3 54.6 422 15.7 573 17.6 16.8
2.6 1028 55.4 1222 51.4 53.2 237 12.8 446 18.8 16.1
2.6 411 52.2 394 49.0 50.6 112 14.2 157 19.5 16.9
9.2 2226 61.9 2032 48.5 54.7 498 13.8 639 15.3 14.6
9.4 1155 57.0 1060 48.7 52.7 292 14.4 390 17.9 16.2
7.7 489 52.0 617 42.4 46.1 181 19.2 331 22.7 21.4
3.6 52 56.5 31 47.7 52.9 10 10.9 11 16.9 13.4
9.3 69 53.9 119 48.4 50.3 15 11.7 35 14.2 13.4
hPG.
Figure 1 Percent of the total sample presenting a glucose abnormality by category and age. Brazilian Longitudinal Study of Adult Health
(ELSA-Brasil), N = 15102, 2008-2010. Smoothing performed using a spline routine (Statistical Analysis System). DM = diabetes mellitus; IGT = impaired
glucose tolerance; iIFG (WHO) = isolated impaired fasting glucose; iIFG(ADA) represents the additional cases of IFG when ascertained by the ADA
criteria; iPre-diabetes by HbA1c represents the additional cases of intermediate hyperglycemia when diagnosed by ADA criteria; WHO=World Health
Organization; ADA = American Diabetes Association. See Methods for diagnostic criteria.
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http://www.dmsjournal.com/content/6/1/123A full understanding of the origins of the global epidemic
of diabetes and intermediate hyperglycemia has yet to be
assembled. Factors possibly related to it, for example, high
sugar consumption, have been little investigated in Brazil.
However, regardless of the multitude of possible causes in-
volved, there is no doubt that the obesity epidemic has
played a major role. Since the obesity burden in Brazil, as in
many settings, is shifting toward the poor [23], this may ex-
plain, in part, the social gradient here described for diabetes
prevalence. Of note, the high prevalence we found among
Asian descendents is consistent with previous studies [24].
Meriting discussion also is the proportion of previously un-
diagnosed diabetes we found, which was similar to that seen
in a Brazilian population survey based on results of an
OGTT (46%), conducted in the late 1980s [4]. We expected
a lower proportion of undiagnosed diabetes in response to
the greater access to health services in recent decades. At
least two reasons may explain our findings. First, when our
undiagnosed cases were ascertained with all possible diag-
nostic tests, their contribution to overall prevalence was
higher than when ascertained only with fasting glucose,
which is still the most common clinical practice. In fact,
when only fasting plasma glucose was used to define undiag-
nosed diabetes, the proportion was lower, only 35.4%. Sec-
ond, the diagnosis of asymptomatic cases of diabetes in
clinical practice requires confirmation on a different day,
while our classification of undiagnosed diabetes (as in most
epidemiologic surveys) was based on only one examination.
Based on published estimates [25], this, by itself, could re-
duce the prevalence of undiagnosed diabetes by 25%.Nevertheless, it is clear that the absolute prevalences of both
diagnosed and undiagnosed diabetes are in rapid ascension
globally [3], and that most previously undetected cases in
our study are likely to represent real cases in the community.
Our study has important strengths, including the size and
diversity of the sample studied and the standardized data
collection. The capacity to fully account for hyperglycemia
and the various means of ascertainment of diabetes and
intermediate hyperglycemia permit a comprehensive de-
scription of the disease burden across relevant socioeco-
nomic groups, which is rarely accomplished in large surveys,
particularly those from low and middle income countries.
Limitations to our study also merit discussion. First,
our sample, consisting of university and research insti-
tute employees with stable employment and a high edu-
cational achievement, is not representative of the entire
Brazilian population. However, as already mentioned, in
terms of self-reported diabetes prevalence, our findings
differ little from those found in a representative sample
of similarly aged adults from Brazil’s capital cities [8].
Moreover, since diabetes prevalence is inversely related
to educational attainment, if a bias is present in our
sample through under-representation of those with less
formal education, it is, if anything, likely to be a conser-
vative one, leading to an underestimation of the preva-
lence of hyperglycemic conditions. Further, since we
based our sample on individuals living in metropolitan
areas, our results are most readily generalized to urban
Brazil, which, according to the 2010 census, is the home
of 84% of the Brazilian population [26].
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http://www.dmsjournal.com/content/6/1/123Second, our ascertainment of previously known dia-
betes may suffer from the increased diabetes and inter-
mediate hyperglycemia screening in recent years, since
participants may tell us, erroneously, that they have dia-
betes when they have lesser than diabetes hyperglycemia.
Further, a positive response to the question about dia-
betes medication use may also inadvertently ascertain
diabetes when in fact the medication was being used to
prevent, rather than to treat diabetes. However, though
they would upwardly bias our prevalences, the effect of
these problems is likely to be small, as shown by the
minimal differences in prevalence seen comparing defi-
nitions 1 and 2 (Table 2).
Within these limitations, we were able to provide an
accurate and full ascertainment of diabetes (previously
diagnosed or not) and intermediate hyperglycemia for a
diverse population of adults living in several Brazilian
capital cities. Specifically, we highlighted a major aggre-
gate burden of these conditions, particularly present in
the elderly, in non-whites, in the obese and in those with
less schooling. Since diabetes has been estimated to de-
crease the lifespan of middle-aged individuals by 6 years
[27], these findings lend support to the current discourse
of the need to address the challenges of diabetes in the
21st century by allocating greater focus and resources to
preventive actions known to be effective [1,28].
This burden, which has increased in Brazil and else-
where in parallel with the climbing rates of obesity and
the aging of the population, is truly a public health dis-
aster in slow motion. For low and middle income coun-
tries, including Brazil, in which the preventive focus
remains largely directed toward infection diseases and
problems of maternal and child health, few public health
preventive actions are currently as important as that of
developing and implementing a strategy to control the
rise of obesity and diabetes. Finally, since diabetes is
more frequent among the less privileged of society, such
actions will additionally contribute to ameliorate health
inequities.
In conclusion, with full accounting, the prevalence of
diabetes and intermediate hyperglycemia is very high, in-
dicating the necessity of public health and clinical pre-
ventive actions.
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